RSV Infection Clinical Trial
Official title:
Impact of the Covid-19 Pandemic on the Epidemiology of Respiratory Syncytial Virus
The magnitude of seasonal Respiratory Syncytial Virus (RSV) epidemics brings each year new logistical challenges for the hospitalization of young infants with bronchiolitis that overwhelm hospital capacities and lead to specific winter plans with deprogramming and mobilization of human and logistical resources. The Covid-19 pandemic has changed the way winter epidemics are presented. For example, the seasonal RSV epidemic was shifted by several months in Lyon, with an impression of a lower incidence of hospitalized cases, with a population of older children and with fewer signs of clinical severity. This is largely attributable to the widespread use of barrier gestures and social distancing measures, known as "Non-Pharmacological Interventions" (NPI). Given the magnitude of the reduction of the RSV epidemic, it is legitimate to analyze the benefits of NPIs to draw lessons for maintaining preventive measures around RSV-vulnerable populations; moreover, new preventive pharmacological interventions are soon to be marketed, whether they are particularly refined and long half-life anti-RSV monoclonal antibodies, RSV vaccines for mothers or for newborns and infants. In this perspective, it is crucial to properly define the populations at risk of severe disease to establish a legitimate hierarchy in the implementation of different preventive strategies. The study of the RSV epidemic is a high potential model because of the convergence of epidemiological, virological, and pharmacological knowledge. However, the study of the impact of the pandemic on the epidemiology of rhinovirus also seems promising because, for reasons unknown to date, it seems that the pandemic did not have the same reducing impact on the rhinovirus epidemic; in the latter case, the interest is to confirm the resistance of this virus and to look for more fundamental explanations, for example, on viral interactions.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03698084 -
RESCEU: Defining the Burden of RSV Disease
|
||
| Recruiting |
NCT05550545 -
Infant RSV Infections and Health-related Quality of Life of Families
|
||
| Completed |
NCT05587478 -
A Study of EDP-323 in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT06180993 -
Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization
|
||
| Suspended |
NCT03909867 -
Emission Patterns of Respiratory Syncytial Virus
|
||
| Recruiting |
NCT06259487 -
Coordinated Vaccination Against RSV and Influenza in Patients With Chronic Heart Failure and Its Impact on Prognosis.
|
N/A | |
| Not yet recruiting |
NCT04144816 -
Predictors of Respiratory Syncytial Virus (RSV) Hospitalizations in Infants
|
||
| Completed |
NCT01090557 -
Exhaled Nitric Oxide in Respiratory Syncytial Virus (RSV) Bronchiolitis: a Pilot Study
|
N/A | |
| Terminated |
NCT01475305 -
Intranasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV)
|
Phase 1 | |
| Not yet recruiting |
NCT05928507 -
FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol
|
||
| Completed |
NCT03062917 -
Nasal and Bronchial Absorption Sampling in RSV Bronchiolitis
|
N/A | |
| Completed |
NCT03691623 -
A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model
|
Phase 2 | |
| Completed |
NCT03387137 -
Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children
|
Phase 1 | |
| Completed |
NCT05070975 -
Severity of RSV Infections in Twins
|
||
| Active, not recruiting |
NCT04938830 -
Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)
|
Phase 3 | |
| Recruiting |
NCT05568706 -
A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.
|
Phase 2 | |
| Completed |
NCT03755778 -
Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01483911 -
ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers
|
Phase 1 | |
| Recruiting |
NCT06170242 -
A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model
|
Phase 2 | |
| Completed |
NCT03750383 -
Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects
|
Phase 1 |